Document is current
Any future updates will be listed below
-
Authors
Jansen, Iris E. http://orcid.org/0000-0003-1901-8131
van der Lee, Sven J. http://orcid.org/0000-0003-1606-8643
Gomez-Fonseca, Duber
de Rojas, Itziar http://orcid.org/0000-0002-2148-381X
Dalmasso, Maria Carolina
Grenier-Boley, Benjamin
Zettergren, Anna http://orcid.org/0000-0002-7182-8417
Mishra, Aniket
Ali, Muhammad http://orcid.org/0000-0002-1399-6631
Andrade, Victor
Bellenguez, Céline
Kleineidam, Luca
Küçükali, Fahri http://orcid.org/0000-0002-3835-9639
Sung, Yun Ju
Tesí, Niccolo
Vromen, Ellen M. http://orcid.org/0000-0001-7774-5500
Wightman, Douglas P.
Alcolea, Daniel http://orcid.org/0000-0002-3819-3245
Alegret, Montserrat http://orcid.org/0000-0002-8164-9500
Alvarez, Ignacio
Amouyel, Philippe
Athanasiu, Lavinia
Bahrami, Shahram
Bailly, Henri
Belbin, Olivia
Bergh, Sverre
Bertram, Lars http://orcid.org/0000-0002-0108-124X
Biessels, Geert Jan http://orcid.org/0000-0001-6862-2496
Blennow, Kaj
Blesa, Rafael
Boada, Mercè
Boland, Anne
Buerger, Katharina
Carracedo, Ángel
Cervera-Carles, Laura http://orcid.org/0000-0003-2286-200X
Chene, Geneviève
Claassen, Jurgen A. H. R. http://orcid.org/0000-0002-1778-8151
Debette, Stephanie
Deleuze, Jean-Francois
de Deyn, Peter Paul http://orcid.org/0000-0002-2228-2964
Diehl-Schmid, Janine
Djurovic, Srdjan http://orcid.org/0000-0002-8140-8061
Dols-Icardo, Oriol
Dufouil, Carole
Duron, Emmanuelle
Düzel, Emrah
,
Fladby, Tormod
Fortea, Juan
Frölich, Lutz
García-González, Pablo http://orcid.org/0000-0003-0125-5403
Garcia-Martinez, Maria
Giegling, Ina
Goldhardt, Oliver
Gobom, Johan
Grimmer, Timo
Haapasalo, Annakaisa
Hampel, Harald
Hanon, Olivier
Hausner, Lucrezia
Heilmann-Heimbach, Stefanie
Helisalmi, Seppo
Heneka, Michael T. http://orcid.org/0000-0003-4996-1630
Hernández, Isabel
Herukka, Sanna-Kaisa
Holstege, Henne
Jarholm, Jonas
Kern, Silke
Knapskog, Anne-Brita
Koivisto, Anne M.
Kornhuber, Johannes http://orcid.org/0000-0002-8096-3987
Kuulasmaa, Teemu
Lage, Carmen
Laske, Christoph
Leinonen, Ville http://orcid.org/0000-0002-4282-4687
Lewczuk, Piotr http://orcid.org/0000-0002-8101-6535
Lleó, Alberto
de Munain, Adolfo López
Lopez-Garcia, Sara
Maier, Wolfgang
Marquié, Marta http://orcid.org/0000-0002-0660-0950
Mol, Merel O. http://orcid.org/0000-0003-2533-2530
Montrreal, Laura
Moreno, Fermin
Moreno-Grau, Sonia
Nicolas, Gael
Nöthen, Markus M.
Orellana, Adelina
Pålhaugen, Lene
Papma, Janne M.
Pasquier, Florence http://orcid.org/0000-0001-9880-9788
Perneczky, Robert
Peters, Oliver
Pijnenburg, Yolande A. L.
Popp, Julius http://orcid.org/0000-0002-0068-0312
Posthuma, Danielle
Pozueta, Ana
Priller, Josef
Puerta, Raquel
Quintela, Inés http://orcid.org/0000-0002-0239-7975
Ramakers, Inez
Rodriguez-Rodriguez, Eloy http://orcid.org/0000-0001-7742-677X
Rujescu, Dan
Saltvedt, Ingvild
Sanchez-Juan, Pascual http://orcid.org/0000-0002-6081-8037
Scheltens, Philip
Scherbaum, Norbert
Schmid, Matthias
Schneider, Anja
Selbæk, Geir http://orcid.org/0000-0001-6511-8219
Selnes, Per
Shadrin, Alexey
Skoog, Ingmar
Soininen, Hilkka
Tárraga, Lluís
Teipel, Stefan
,
Tijms, Betty http://orcid.org/0000-0002-2612-1797
Tsolaki, Magda
Van Broeckhoven, Christine
Van Dongen, Jasper http://orcid.org/0000-0001-5599-0046
van Swieten, John C.
Vandenberghe, Rik
Vidal, Jean-Sébastien
Visser, Pieter J.
Vogelgsang, Jonathan
Waern, Margda http://orcid.org/0000-0002-8330-6915
Wagner, Michael http://orcid.org/0000-0003-2589-6440
Wiltfang, Jens
Wittens, Mandy M. J.
Zetterberg, Henrik http://orcid.org/0000-0003-3930-4354
Zulaica, Miren
van Duijn, Cornelia M. http://orcid.org/0000-0002-2374-9204
Bjerke, Maria
Engelborghs, Sebastiaan http://orcid.org/0000-0003-0304-9785
Jessen, Frank
Teunissen, Charlotte E.
Pastor, Pau
Hiltunen, Mikko
Ingelsson, Martin
Andreassen, Ole A. http://orcid.org/0000-0002-4461-3568
Clarimón, Jordi
Sleegers, Kristel http://orcid.org/0000-0002-0283-2332
Ruiz, Agustín
Ramirez, Alfredo http://orcid.org/0000-0003-4991-763X
Cruchaga, Carlos http://orcid.org/0000-0002-0276-2899
Lambert, Jean-Charles
van der Flier, Wiesje http://orcid.org/0000-0001-8766-6224
-
Funding
Funding for this research was provided by:
EU Joint Programme – Neurodegenerative Disease Research (European Alzheimer DNA BioBank, EADB)
- License Information
-
More Information
Article History
Received: 16 February 2022
Revised: 18 May 2022
Accepted: 7 June 2022
First Online: 6 September 2022
Declarations
:
: Research programs of Wiesje van der Flier have been funded by ZonMW, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, CardioVascular Onderzoek Nederland, Health ~ Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Pasman stichting, stichting Alzheimer & Neuropsychiatrie Foundation, Biogen MA Inc, Boehringer Ingelheim, Life-MI, AVID, Roche BV, Fujifilm, Combinostics. WF holds the Pasman chair. WF is recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health ~ Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). WF has performed contract research for Biogen MA Inc, and Boehringer Ingelheim. WF has been an invited speaker at Boehringer Ingelheim, Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), Springer Healthcare. WF is consultant to Oxford Health Policy Forum CIC, Roche, and Biogen MA Inc. WF participated in advisory boards of Biogen MA Inc and Roche. All funding is paid to her institution. WF was associate editor of Alzheimer, Research & Therapy in 2020/2021. WF is associate editor at Brain. CC receives research support from: Biogen, EISAI, Alector and Parabon. The funders of the study had no role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. CC is a member of the advisory board of Vivid genetics, Halia Therapeutics and ADx Healthcare. HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KBlennow has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. OAA is a consultant to HealthLytix, and received speaker’s honorarium from Lundbeck and Sunovion. SE has served at scientific advisory boards for Biogen, Danone, Eisai, icometrix, Pfizer, Novartis, Nutricia, Roche and has received unrestricted research grants from ADx Neurosciences and Janssen Pharmaceutica. CC receives research support from: Biogen, EISAI, Alector, GSK and Parabon. The funders of the study had no role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. CC is a member of the advisory board of Vivid genetics, Halia Therapeutics and ADx Healthcare. HHampel is an employee of Eisai Inc. and serves as Senior Associate Editor for the Journal Alzheimer’s & Dementia; during the past three years he had received lecture fees from Servier, Biogen and Roche, research grants from Pfizer, Avid, and MSD Avenir (paid to the institution), travel funding from Eisai, Functional Neuromodulation, Axovant, Eli Lilly and company, Takeda and Zinfandel, GE-Healthcare and Oryzon Genomics, consultancy fees from Qynapse, Jung Diagnostics, Cytox Ltd., Axovant, Anavex, Takeda and Zinfandel, GE Healthcare, Oryzon Genomics, and Functional Neuromodulation, and participated in scientific advisory boards of Functional Neuromodulation, Axovant, Eisai, Eli Lilly and company, Cytox Ltd., GE Healthcare, Takeda and Zinfandel, Oryzon Genomics and Roche Diagnostics. DA participated in advisory boards from Fujirebio-Europe and Roche Diagnostics and received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmacéutica S.L., Zambon S.A.U. and Esteve Pharmaceuticals S.A. OG reports consulting fees from Eli Lilly, grants to his institution from Actelion, and prescreening activities for Julius Clinical/Toyama. ABK has been a PI in the drug trials Roche BN29553, Boehringer-Ingelheim 1346.0023 and is PI in Novo Nordisk NN6535-4730. AL has received personal fees for advisory board services and/or speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia,Krka Farmacéutica SL, Biogen and Zambon. PSJ has received personal fees for advisory board from Roche Diagnostics and Zambon. GS participated in one advisory board meeting from Biogen. MI is a paid consultant to BioArctic AB. KS is editor at Acta Neuropathologica and associate editor at Alzheimer’s Research & Therapy. HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). All other authors declare no financial interests or potential conflicts of interest.
